GLP1-RAs are incretin medications that increase the production of glucose-dependent insulin, suppress the release of glucagon from pancreatic α cells in hyperglycemia states, diminish the stomach’s emptying, and affect appetite, resulting in a decrease in food consumption [96]. This evidence concerns the gene INS and Hyperglycemia.